Vista Klinik
10
2
2
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
10.0%
1 terminated/withdrawn out of 10 trials
85.7%
-0.8% vs industry average
50%
5 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
Role: collaborator
Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
Role: collaborator
Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept
Role: lead
Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept
Role: lead
Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab
Role: lead
Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy
Role: lead
Correlation Between Visual Acuity Measurements, Quality of Life and Morphological Parameters in Wet AMD Patients
Role: collaborator
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
Role: lead
Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
Role: lead
Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy
Role: lead
All 10 trials loaded